Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-29 | Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. |
| 2020-04-24 | Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. |
| 2021-04-27 | Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme© for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for BristolMyers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III (NASDAQ: ARYA) and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. |
| 2022-04-26 | He received a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School. |
| 2023-04-26 | He received a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School. |
| 2024-04-24 | He received a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22